Atlas Trials

Rhizen Pharmaceuticals SA

17 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Rhizen Pharmaceuticals SA

RecordFirmDate
Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) (NCT06189209)Rhizen Pharmaceuticals SA2024-03-04
Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL (NCT05239910)Rhizen Pharmaceuticals SA2023-01-01
Efficacy and Safety of Tenalisib (RP6530), in Patients With Locally Advanced or Metastatic Breast Cancer (NCT05021900)Rhizen Pharmaceuticals SA2021-10-13
Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors (NCT05002868)Rhizen Pharmaceuticals SA2021-10-05
Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection. (NCT05007236)Rhizen Pharmaceuticals SA2021-09-20
A Single and Multiple Ascending and Food Effect Study of RP7214, a DHODH Inhibitor in Healthy Adult Subjects (NCT04680429)Rhizen Pharmaceuticals SA2020-12-29
Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) (NCT04204057)Rhizen Pharmaceuticals SA2019-11-28
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma (NCT03770000)Rhizen Pharmaceuticals SA2019-03-12
Compassionate Use Study of Tenalisib (RP6530) (NCT03711604)Rhizen Pharmaceuticals SA2018-11-28
Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) (NCT03711578)Rhizen Pharmaceuticals SA2018-11-25
Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL (NCT03471351)Rhizen Pharmaceuticals SA2018-07-18

Track Rhizen Pharmaceuticals SA automatically

Every clearance here is in the API, with alerts when new ones post.